On October 19, Bitcoin was priced at $82,546 while Coinbase's spot market showed $1.9 million more sell orders than buy orders, indicating a sell-side imbalance. Other major markets like Binance, OKX, and Hyperliquid also showed similar sell order dominance, though the gaps varied. This shift contrasts with October 17, when buy orders exceeded sell orders by $1.67 million on Coinbase. Such imbalances could lead to sharper price moves, especially on platforms with thinner order books.
Bitcoin spot sell orders on Coinbase exceeded buy orders by $1.9 million on October 19, 2026. For readers following cryptocurrency markets, here is Pluang's snapshot as of Oct 19, 2026 15:02 WIB: 41 of 50 major cryptocurrencies rose, 8 fell. Enjin Coin (ENJ) dropped 2.15% with 95% sell orders, Fantom (FTM) fell 2.05%, and Decentraland (MANA) declined 2.05% with a slight buy order majority at 53%.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
